Cambiogenplasmid

Trade name: neovasculgen

Gene therapyexperimental

Cambiogenplasmid, marketed as Neovasculgen, is a gene therapy drug for treatment of peripheral artery disease, including critical limb ischemia; it delivers the gene encoding for vascular endothelial growth factor (VEGF). Neovasculogen is a plasmid encoding the CMV promoter and the 165 amino acid form of VEGF. It was developed by the Human Stem Cells Institute in Russia and approved in Russia in 2011. — Wikipedia

Clinical trial activity

6 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
2

Earliest trial started Feb 1, 2010 (NCT03068585)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • neovasculgen

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06473740Phase 4Jun 20, 2024Amur State Medical Academy
NCT02538705N/AAug 1, 2015Human Stem Cell Institute, Russia, Pavlov First Saint Petersburg State Medical University, Vidnoe District Hospital
NCT02352649Phase 1/Phase 2 (Phase 2)Apr 1, 2015Human Stem Cell Institute, Russia, Kazan Federal University
NCT02356809Phase 1/Phase 2 (Phase 2)Mar 1, 2015Human Stem Cell Institute, Russia, Russian Academy of Medical Sciences
NCT02369809Phase 4Sep 1, 2012Human Stem Cell Institute, Russia
NCT03068585Phase 2/Phase 3 (Phase 3)Feb 1, 2010Human Stem Cell Institute, Russia
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Human Stem Cell Institute, RussiaAcademic/Hospital5542010
Amur State Medical AcademyAcademic/Hospital1112024
Kazan Federal UniversityAcademic/Hospital1012015
Pavlov First Saint Petersburg State Medical UniversityAcademic/Hospital1012015
Russian Academy of Medical SciencesAcademic/Hospital1012015
Vidnoe District HospitalAcademic/Hospital1012015
6 organizations
Page 1 / 1